Role of Resmetirom, a Liver-Directed, Thyroid Hormone Receptor Beta-Selective Agonist, in Managing Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis
-
Published:2024-07
Issue:7
Volume:30
Page:631-638
-
ISSN:1530-891X
-
Container-title:Endocrine Practice
-
language:en
-
Short-container-title:Endocrine Practice
Author:
Dutta DeepORCID,
Kamrul-Hasan A.B.M.ORCID,
Mondal ErshadORCID,
Nagendra LakshmiORCID,
Joshi AmeyaORCID,
Bhattacharya SaptarshiORCID
Reference22 articles.
1. Mechanisms and disease consequences of nonalcoholic fatty liver disease;Loomba;Cell,2021
2. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis;Riazi;Lancet Gastroenterol Hepatol,2022
3. The increasing clinical burden of NAFLD in Asia;De Roza;Lancet Gastroenterol Hepatol,2019
4. Treatments for NAFLD: state of art;Mantovani;Int J Mol Sci,2021
5. Discovery of 2-[3,5-Dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β Agonist in Clinical Trials for the Treatment of Dyslipidemia
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献